← Back to Search

Tyrosine Kinase Inhibitor

Crizotinib for Cancer

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Type, incidence, severity, seriousness and relationship to study medication of adverse events and any laboratory abnormalities
Overall Response Rate
Secondary outcome measures
Duration of Response
Overall Survival
Phosphorylation status of ALK in the tumor samples from surgery or biopsy pre and post treatment when available
+3 more

Side effects data

From 2020 Phase 3 trial • 207 Patients • NCT01639001
55%
White blood cell count decreased
50%
Nausea
49%
Anaemia
46%
Vomiting
45%
Alanine aminotransferase increased
37%
Neutropenia
35%
Aspartate aminotransferase increased
33%
Neutrophil count decreased
33%
Decreased appetite
27%
Constipation
27%
Platelet count decreased
24%
Cough
21%
Haemoglobin decreased
20%
Leukopenia
17%
Chest pain
17%
Fatigue
16%
Blood albumin decreased
16%
Hyponatraemia
15%
Pyrexia
13%
Back pain
11%
Dizziness
11%
Dyspnoea
11%
Alopecia
10%
Thrombocytopenia
10%
Asthenia
9%
Diarrhoea
9%
Headache
9%
Insomnia
9%
Red blood cell count decreased
8%
Phlebitis
8%
Visual impairment
8%
Upper respiratory tract infection
8%
Nasopharyngitis
8%
Hypoalbuminaemia
8%
Haemoptysis
8%
Pruritus
7%
Rash
7%
Hypokalaemia
6%
Blood bilirubin increased
6%
Lymphocyte count decreased
6%
Pain in extremity
6%
Abdominal distension
6%
Pain
6%
Productive cough
5%
Oedema peripheral
5%
Musculoskeletal pain
4%
Arthralgia
4%
Vision blurred
4%
Chest discomfort
4%
Blood alkaline phosphatase increased
4%
Gamma-glutamyltransferase increased
4%
Paraesthesia
4%
Hypocalcaemia
3%
Abdominal pain
3%
Protein total decreased
2%
Abdominal pain upper
2%
Hypoaesthesia
1%
Pleural effusion
1%
Disease progression
1%
Death
1%
Blood creatinine increased
1%
Pneumonia
1%
Oedema
1%
Blood lactate dehydrogenase increased
1%
Hypoproteinaemia
1%
Hypertension
1%
Pericardial effusion
1%
Syncope
1%
Transaminases increased
1%
Cerebral infarction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Chemotherapy
Crizotinib

Trial Design

1Treatment groups
Experimental Treatment
Group I: CrizotinibExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Crizotinib
FDA approved

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,568 Previous Clinical Trials
10,911,842 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,475 Previous Clinical Trials
8,093,010 Total Patients Enrolled

Media Library

Crizotinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01121588 — Phase 1
Cancer Research Study Groups: Crizotinib
Cancer Clinical Trial 2023: Crizotinib Highlights & Side Effects. Trial Name: NCT01121588 — Phase 1
Crizotinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01121588 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any past investigations concerning Crizotinib?

"Crizotinib first appeared in a study conducted by SUN Yat-Sen University Cancer Center back in 2011 and since then there have been 44 trials concluded. Currently, 32 trails worldwide are active with several of them situated in Portland, Oregon."

Answered by AI

Does this medical experiment represent an unprecedented approach to treatment?

"Crizotinib is being tested in 32 active trials spread across 36 nations and 1204 cities. Pfizer initiated the first of these studies back in 2011, recruiting 44 people for a Phase 1 approval stage that was ultimately successful. Since then, an additional 44 research projects have been completed."

Answered by AI

Does Crizotinib have the blessing of the Food and Drug Administration?

"The safety profile of Crizotinib was appraised at 1 since this is a Phase 1 clinical trial, meaning that there are only limited data to support its efficacy and security."

Answered by AI

How many individuals are enrolled in this experiment?

"This clinical trial has since concluded, as the last update was recorded on September 21st 2022. If you are searching for other trials related to lymphoma and Crizotinib, there are currently 3954 studies recruiting patients and 32 that involve use of the latter medication."

Answered by AI

Are there still participation opportunities for this scientific experiment?

"This medical trial is no longer recruiting participants, with its first posting on March 22nd 2011 and last edit occurring on September 21st 2022. However, there are 3954 studies looking for lymphoma patients and 32 trials that utilize Crizotinib currently seeking volunteers."

Answered by AI

At what number of venues is this inquiry being conducted?

"The ongoing trial is enrolling patients at 10 sites, including Portland, Saint Louis and Springdale. We recommend selecting the closest site to reduce travel requirements if you take part in this study."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
2011. "An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01121588.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top